

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Sawai USA, Inc., Sawai Pharmaceutical Co., Ltd.,
Petitioners,

v.

Nissan Chemical Industries Ltd.,
Patent Owner

U.S. Patent No. 5,856,336

Issue Date: January 5, 1999

Title: Quinoline Type Mevalonolactones

Inter Partes Review No. IPR2015-01647

**PATENT OWNER'S MANDATORY DISCLOSURES
UNDER 37 C.F.R. § 42.8**

I. 37 C.F.R. § 42.8(b)(1) – NOTICE OF REAL PARTY IN INTEREST

The real parties in interest are Nissan Chemical Industries, Ltd., Kowa Company, Ltd., and Kowa Pharmaceuticals America, Inc.

II. 37 C.F.R. § 42.8(b)(2) – RELATED MATTERS

A Petition for *inter partes* review of U.S. Patent No. 5,856,336 (the “‘336 Patent”), IPR2015-01069, was filed on April 18, 2015 by Mylan Pharmaceuticals Inc. At the time of this filing, the Board has not decided whether or not to institute review in that proceeding.

The Petitioners in this proceeding also filed an additional petition for *inter partes* review of the same ‘336 Patent on the same date, July 31, 2015. *See* IPR 2015-01648.

Plaintiffs assert that defendants in the following litigations infringe the ‘336 Patent: *Kowa Company, Ltd., et. al. v. Amneal Pharmaceuticals, LLC*, 1:14-cv-02758 (S.D.N.Y., April 17, 2014); *Kowa Company, Ltd., et. al. v. Aurobindo Pharma Limited, et. al.*, 1:14-cv-02497 (S.D.N.Y., April; 9, 2014); *Kowa Company, Ltd., et. al. v. Mylan, Inc., et. al.*, 1:14-cv-02647 (S.D.N.Y., April 14, 2014); *Kowa Company, Ltd., et. al. v. Orient Pharma Co., Ltd.*, 1:14-cv-02759 (S.D.N.Y., April 17, 2014); *Kowa Company, Ltd., et. al. v. Sawai USA, Inc, et. al.*, 1:14-cv-05575 (S.D.N.Y., July 23, 2014); and *Kowa Company, Ltd., et. al. v.*

Zydus Pharmaceuticals (USA) Inc., et. al., 1:14-cv-02760 (S.D.N.Y., April 17, 2014).

III. 37 C.F.R. § 42.8(b)(3) – LEAD AND BACKUP COUNSEL

Lead Counsel: David G. Conlin (Reg. No. 27,026); Tel.: 617-348-1856; Fax: 617-542-2241; Address: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111; email: DGConlin@mintz.com.

Backup Counsel: Kathleen B. Carr (Reg. No. 41,658); Tel.: 617-348-1857; Fax: 617-542-2241; Address: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111; email: KBCarr@mintz.com; David Cotta (Reg. No. 52,771); Tel.: 617-348-1861 Fax: 617-542-2241; Address: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111; email: DCotta@mintz.com; Peter J. Cuomo (Reg. No. 58,481); Tel.: 617-348-1854; Address: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111; email: PJCuomo@mintz.com.

IV. 37 C.F.R. § 42.8(b)(4) – SERVICE INFORMATION

Please direct all correspondence to lead counsel and backup counsel at the contact information above. Patent Owner consents to service by electronic mail at all of the following email addresses:

DGConlin@mintz.com
KBCarr@mintz.com
DCotta@mintz.com
PJCuomo@mintz.com

Respectfully submitted,

NISSAN CHEMICAL INDUSTRIES,
LTD.,

By its attorneys,

/David G. Conlin/

David G. Conlin, Reg. No. 27,026
Kathleen B. Carr, Reg. No.41,658
Mintz, Levin, Cohn, Ferris, Glovsky and
Popeo, P.C.

One Financial Center

Boston, MA 02111

617-542-6000

617-542-2241 fax

DGConlin@mintz.com

KBCarr@mintz.com

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing Patent Owner's Mandatory Notice was served on August 20, 2015 by sending a copy by overnight courier and by email to:

Kenneth J. Burchfiel
Sughrue Mion, PLLC
2100 Pennsylvania Ave., NW
Washington, DC 20037
Phone: 202-293-7060
Fax: 202-293-7860
kburchfiel@sughrue.com

/David G. Conlin/
David G. Conlin
Reg. No. 27,026